How was CATIE conducted?
Study Participants and Sites. The CATIE clinical trials included 1,460[2] participants at 57 clinical sites across the country. • Participants in the study ranged in age from 18 to 65 years old, and all had a diagnosis of schizophrenia (individuals experiencing first-time episodes and treatment-refractory schizophrenia were excluded from the study). Seventy-four percent of the participants were male. • Many participants had co-occurring health and mental health problems, such as depression (28% of participants), anxiety (at least 14%), drug dependence/abuse (29%), diabetes (11%) and hypertension (20%). • Sixty percent of participants identified themselves as white/Caucasian; 35% as African American/Black; 12% as Spanish, Hispanic or Latino; 2% as Asian; less than 1% as American Indian or Alaska Native; less than 1% as Native Hawaiian or other Pacific Islander; and 2% as “two or more races.”[3] • According to researchers at an NIMH briefing on September 26, 2005, about 30% of CATIE part
